Search
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalThe prodrug formulation of isavuconazole is FDA- and EMA-approved and is marketed under the trade name Cresemba for the treatment of invasive aspergillosis and mucormycosis as oral or intravenous administration … It is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026].
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersCimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalA histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. … It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Mixtures: Cimetidine 5% / Ibuprofen 2% / Salicylic Acid 17%, Cimetidine 10% / Lidocaine 5% / Salicylic Acid 40%Categories: MATE 1 Inhibitors, MATE 1 SubstratesPropoxycaine
go.drugbank.com/drugs/DB09342ApprovedThis drug was removed from the US market in 1996. … Propoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride [L1588].
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation … antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation.
Mixtures: ALERMED® D, FEXU D® SUSPENSIONCategories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingPexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigational[L7901] Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. … Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalMyasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in … [A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersInternational brands: Kalymin NPlasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.
Synonyms: 1-glutamylplasminogenLuspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigationalLuspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood
Products: REBLOZYL®Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. … The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular
Synonyms: 2-((diphenylmethyl)sulfinyl)acetamideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. … [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates